BioCryst Pharmaceuticals, Inc.
BCRX
Positions held
Your positionsBCRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- BioCryst Pharmaceuticals is well-positioned in the specialty drug manufacturing sector, focusing on innovative treatments that address unmet medical needs.
- Revenue increased by 40% compared to the prior quarter, reaching $218 million.
- Gross margin improved to 98.2%, up from 96.6% in the previous quarter.
- The company has a strong sell signal with a score of -23.00, indicating significant bearish sentiment among analysts.
- Net income for 2026-Q1 was -721.812 million, reflecting ongoing financial challenges.
- Operating margin for 2026-Q1 was -448.55%, highlighting severe operational difficulties.
Fundamentals
| Market cap | $2.12B | Enterprise value | $2.60B | Trailing P/E | — | Forward P/E | 8.82 |
| PEG | 9.39 | Price / book | -4.66 | Beta | 0.55 | Dividend yield | 0.00% |
| Revenue growth | 33.6% | Earnings growth | 1400.0% | Gross margin | 77.4% | Operating margin | 45.1% |
| Profit margin | -40.9% | ROE | — | ROA | 52.9% | Debt / equity | — |
| Current ratio | 2.32 | Free cash flow | $323.67M | Analyst recommendation | buy | Mean target | $20.73 |
| 52w high | $11.22 | 52w low | $6.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M |
| Op margin | 45.1% | -448.6% | 64.0% | 18.6% | 18.2% |
| Net income | $78.4M | -$722M | $246M | $12.9M | $5.1M |
| Gross margin | 98.2% | 96.6% | 97.7% | 98.6% | 98.3% |
| Gross profit | $214M | $151M | $397M | $157M | $161M |
| Operating income | $98.5M | -$702M | $260M | $29.6M | $29.8M |
- Revenue +40% vs prior quarter ($218M vs $156M).
- Gross margin 98.2% (was 96.6% prior quarter).
- Operating margin expanded to 45.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | — |
| Op margin | 39.0% | -0.6% | -31.3% | -54.8% | — |
| Net income | $264M | -$88.9M | -$227M | -$247M | — |
| Gross margin | 97.8% | 97.3% | 98.6% | 97.6% | — |
| Gross profit | $856M | $438M | $327M | $264M | — |
| Operating income | $341M | -$2.5M | -$104M | -$148M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves
2026-10-05 · BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
2026-09-29 · Claude AI Just Bought These 2 Pharma Stocks
2026-09-23 · Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks?
2026-09-21 · Biopharma Stock With Layers of Technical Support in Place
2026-09-19 · BioCryst Eyes $1B Rare-Disease Future Through External Innovation
2026-09-18 · 4 Biotech Stocks to Watch as Potential Takeover Targets
2026-09-17 · BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
2026-09-15 · PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
2026-09-14 · BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story
2026-09-10 · Sector Update: Healthcare Stocks Softer in Afternoon Trading
Price (daily)
Full chart · RSI · MACD · patterns